Kathy S. Albain, MD

Articles by Kathy S. Albain, MD

31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

ByAditya Bardia, MD, MPH, FASCO,Lajos Pusztai, MD, DPhil,Kathy S. Albain, MD,Kevin Kalinsky, MD, MS,Dawn Herman,William Barlow,Claudine Isaacs, MD,Micah Maxwell,Nadia Harbeck, MD, PhD,Priyanka Sharma, MD

April 27th 2023

Induction Chemotherapy With/Without Radiation Followed by Surgery in Stage III Non-Small-Cell Lung Cancer

ByKathy S. Albain, MD

September 1st 1997

The objectives of this review are to provide an update and perspectives on the use of induction therapy (chemotherapy with or without radiotherapy) followed by surgery in two subgroups of patients with stage III non-

Latest Updated Articles

Induction Chemotherapy With/Without Radiation Followed by Surgery in Stage III Non-Small-Cell Lung Cancer
September 1st 1997

Kathy S. Albain, MD

Articles by Kathy S. Albain, MD

31 TIP TROPION-Breast03: Datopotamab Deruxtecan (Dato-DXd) ± Durvalumab vs Investigator’s Choice of Therapy (ICT) for Triple-Negative Breast Cancer (TNBC) with Residual Disease Following Neoadjuvant Therapy

Induction Chemotherapy With/Without Radiation Followed by Surgery in Stage III Non-Small-Cell Lung Cancer

Latest Updated Articles

Trending on CancerNetwork

FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma

The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?

Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma

Developers Initiate Phase 2/3 Ivonescimab/EV Trial in Bladder Cancer

GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology